Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sheng Bai oral liquid for chemotherapy-induced neutropenia in non-small cell lung cancer
ChiCTR1800014538Phase 4Recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Jan 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Shengbai oral liquid in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guang'anmen Hospital. Primary endpoints: Incidence and severity of neutropenia and Recovery time of neutropenia. Started Jan 2018; status: recruiting.
02
Drugs
Shengbai oral liquid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800014538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014538.